Anti-GAPDS antibody

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-GAPDS antibody (AB153802)

Paraffin embedded human gastric cancer tissue stained for GAPDHS using ab153802 at 1/500 dilution in immunohistochemical analysis.

• ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-GAPDS antibody (AB153802)

Immunofluorescent analysis of methanol-fixed MCF7 cells labeling GAPDS with ab153802 at 1/200 dilution. Lower panel co-stained with Hoechst 33342.

• WB

Unknown

Western blot - Anti-GAPDS antibody (AB153802)

10% SDS PAGE

All lanes:

Western blot - Anti-GAPDS antibody (ab153802) at 1/1000 dilution

All lanes:

MCF7 whole cell lysate at 30 µg

Predicted band size: 45 kDa,49 kDa

false

• WB

Supplier Data

Western blot - Anti-GAPDS antibody (AB153802)

10% SDS-PAGE

All lanes:

Western blot - Anti-GAPDS antibody (ab153802) at 1/500 dilution

All lanes:

Mouse testis tissue extract at 50 µg

Predicted band size: 45 kDa

false

• WB

Unknown

Western blot - Anti-GAPDS antibody (AB153802)

10% SDS PAGE

All lanes:

Western blot - Anti-GAPDS antibody (ab153802) at 1/5000 dilution

All lanes:

NIH/3T3 whole cell lysate at 30 µg

Predicted band size: 45 kDa

false

• WB

CiteAb

Western blot - Anti-GAPDS antibody (AB153802)

Western Blotting using Anti-GAPDS antibody, ab153802. Publication image from He, J. et al., 2020, Mol Cancer, 31992303. Legend direct from paper.

circ-MAPK4 behaved as an oncogene in glioma cells. (a) Circ-MAPK4 is also highly expressed in glioma cell lines, especially in U138 and U373, when compared to gial cell line (HA1800). (b) Schematic representation of target sequences of siRNAs which specially silence circ-MAPK4. (c) The silence efficiency of siRNA targeting to circMAPK4 was analyzed by qPCR after transfected for 48 h in either U138 or U373 cells. (d) CCK-8 assays were performed to test survival of U138 and U373 cells after silencing of circ-MAPK4. (e) Colony formation assays were performed to test survival of U138 and U373 cells after silencing of circ-MAPK4. (f) Apoptosis assays were used to detect apoptosis levels of circ-MAPK4 silenced U138 and U373 cells. (g) Western blot assays were performed to analyze the protein expression levels of cleaved form of caspase-9, caspase-7, caspase-3, and PARP1 in circ-MAPK4 silenced U138 and U373 cells. (h) Transwell assays were carried out to test the invasive activity of circ-MAPK4 silenced U138 and U373 cells. The results above were summarized as bar graph. All data are the means ± SEM of three experiments. *P < 0.05; **P < 0.01; ***P < 0.001

false

• WB

CiteAb

Western blot - Anti-GAPDS antibody (AB153802)

Western Blotting using Anti-GAPDS antibody, ab153802. Publication image from He, J. et al., 2020, Mol Cancer, 31992303. Legend direct from paper.

Inhibition of phosphorylation of p38/MAPK reverses cell survival induced by circ-MAPK4. (a) U373 cells transfected with siRNA negative control, circ-MAPK4 siRNA-1 and siRNA-2 were treated with or without p-p38/MAPK inhibitor (SB203580). Inhibition efficiency of p-p38/MAPK inhibitor was accessed by testing phosphorylation and total protein levels of p38/MAPK and ERK using western blot assays. (b, c) CCK-8 and colony formation assays were performed to reveal cell survival of these U373 cells. (d) Apoptosis assays were performed to reveal apoptosis levels of these U373 cells. (e) The western blot assays were used to evaluate effect of p-p38/MAPK inhibitor on protein expression levels of cleaved form of caspase-9, caspase-7, caspase-3, PARP1 in these U373 cells. The data were summarized as bar graph. Data are the means ± SEM of three experiments. *P < 0.05; **P < 0.01; ***P < 0.001

false